Status:
UNKNOWN
Anti-HLA Immunization And Immunosuppressive Therapy Management In Kidney Transplant Patients Returning to Dialysis
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Kidney Transplantation
Immunosuppressive Agents
Eligibility:
All Genders
Brief Summary
This study is an analytical observational retrospective cohort study. It is a single-center study conducted in the Nancy University Hospital. End stage renal disease is the ultimate stage of the chro...
Detailed Description
Cohort constitution : The cohort of patients returning to dialysis after graft loss is extracted from the REIN (Réseau Epidémiologique et Information en Néphrologie) Lorraine registry, which follow a...
Eligibility Criteria
Inclusion
- Patients included in the Lorraine regional REIN registry over the period 2007-2019,
- Returning in dialysis after a kidney transplantation, with a living or deceased donor.
- On haemodialysis or peritoneal dialysis.
- Registered or not on the waiting-list for retransplantation
Exclusion
- Patients with graft dysfunction receiving a pre-emptive retransplantation
- Absence of serum tested for anti-HLA (human leukocyte antigen) antibodies after the return to dialysis.
- No information on immunosuppressive agents
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
430 Patients enrolled
Trial Details
Trial ID
NCT05282875
Start Date
February 1 2022
End Date
September 1 2022
Last Update
April 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central HNF
Nancy, Lorraine, France, 54000